Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Hisashi Oishi"'
Autor:
Toshikazu Watanabe, Takashi Hirama, Ken Onodera, Hirotsugu Notsuda, Hisashi Oishi, Hiromichi Niikawa, Kazuyoshi Imaizumi, Yoshinori Okada
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background Interstitial lung disease (ILD) represents a heterogeneous group of lung disorders characterized by fibrotic lung tissue changes. In regions with severe donor shortages, single-lung transplantation (SLTx) is often preferred over b
Externí odkaz:
https://doaj.org/article/892534cc754c41a5aa095cac140a347e
Autor:
Takashi Hirama, Miki Akiba, Tatsuaki Watanabe, Yui Watanabe, Hirotsugu Notsuda, Hisashi Oishi, Hiromichi Niikawa, Yoshinori Okada
Publikováno v:
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background As lung transplantation (LTX) is a valuable treatment procedure for end-stage pulmonary disease, delayed referral to a transplant center should be avoided. We aimed to conduct a single-center analysis of the survival time after li
Externí odkaz:
https://doaj.org/article/16ec813a4810479a9d560315d217dc71
Autor:
Takashi Hirama, Fumiko Tomiyama, Hirotsugu Notsuda, Tatsuaki Watanabe, Yui Watanabe, Hisashi Oishi, Yoshinori Okada
Publikováno v:
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background While lung transplant (LTX) can be an effective therapy to provide the survival benefit in selected populations, post-transplant outcome in LTX recipients with bronchiectasis other than cystic fibrosis (CF) has been less studied.
Externí odkaz:
https://doaj.org/article/fc66ee933224472ab4d6d40f1d8a02aa
Autor:
Etsuhiro Nikkuni, Takashi Hirama, Kazuki Hayasaka, Sakiko Kumata, Shinichi Kotan, Yui Watanabe, Hisashi Oishi, Hiromichi Niikawa, Masahiro Kohzuki, Yoshinori Okada
Publikováno v:
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Lung transplant (LTX) can provide a survival benefit and improve physical function for selected patients with advanced pulmonary disease. Sarcopenia is a systemic muscle-failure that can be found in a variety of life stages and di
Externí odkaz:
https://doaj.org/article/33b79e46f744458d846e0f3f5ad6b7ec
Autor:
Sakiko Kumata, Takashi Hirama, Yui Watanabe, Hisashi Oishi, Hiromichi Niikawa, Miki Akiba, Jussi Tikkanen, Yoshinori Okada
Publikováno v:
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background Anti-human leukocyte antigen (HLA) antibody testing was approved by the Japanese government in 2018. As such, there was no longitudinal data regarding the HLA-sensitization of lung transplant (LTX) patients in Japan. We therefore
Externí odkaz:
https://doaj.org/article/cb1eead47a3f412cbebd8c68ee0c5aac
Autor:
Miki Akiba, Tatsuaki Watanabe, Yui Watanabe, Hisashi Oishi, Hirotsugu Notsuda, Yoshinori Okada, Hiromichi Niikawa, Takashi Hirama
Publikováno v:
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Pulmonary Medicine
BMC Pulmonary Medicine
Background As lung transplantation (LTX) is a valuable treatment procedure for end-stage pulmonary disease, delayed referral to a transplant center should be avoided. We aimed to conduct a single-center analysis of the survival time after listing for
Autor:
J. Tikkanen, Sakiko Kumata, Hisashi Oishi, Yui Watanabe, Hiromichi Niikawa, Yoshinori Okada, Takashi Hirama, Miki Akiba
Publikováno v:
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-8 (2020)
BMC Pulmonary Medicine
BMC Pulmonary Medicine
Background Anti-human leukocyte antigen (HLA) antibody testing was approved by the Japanese government in 2018. As such, there was no longitudinal data regarding the HLA-sensitization of lung transplant (LTX) patients in Japan. We therefore set out t
Autor:
Tatsuaki Watanabe, Yui Watanabe, Yoshinori Okada, Fumiko Tomiyama, Hisashi Oishi, Hirotsugu Notsuda, Takashi Hirama
Publikováno v:
BMC Pulmonary Medicine
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-10 (2021)
BackgroundWhile lung transplant (LTX) can be an effective therapy to provide the survival benefit in selected populations, post-transplant outcome in LTX recipients with bronchiectasis other than cystic fibrosis (CF) has been less studied.Pseudomonas
Autor:
Hiromichi Niikawa, Sakiko Kumata, Yoshinori Okada, Masahiro Kohzuki, Etsuhiro Nikkuni, Yui Watanabe, Hisashi Oishi, Kazuki Hayasaka, Takashi Hirama, Shinichi Kotan
Publikováno v:
BMC Pulmonary Medicine
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-10 (2021)
Background Lung transplant (LTX) can provide a survival benefit and improve physical function for selected patients with advanced pulmonary disease. Sarcopenia is a systemic muscle-failure that can be found in a variety of life stages and disabilitie